Wells Fargo & Company MN Sells 55,319 Shares of Intra-Cellular Therapies Inc. (ITCI)

Wells Fargo & Company MN lessened its stake in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 62.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 32,876 shares of the biopharmaceutical company’s stock after selling 55,319 shares during the period. Wells Fargo & Company MN owned 0.08% of Intra-Cellular Therapies worth $409,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Federated Investors Inc. PA grew its holdings in Intra-Cellular Therapies by 113.3% during the second quarter. Federated Investors Inc. PA now owns 183,035 shares of the biopharmaceutical company’s stock valued at $2,273,000 after purchasing an additional 97,228 shares during the period. Dimensional Fund Advisors LP grew its holdings in Intra-Cellular Therapies by 192.2% during the first quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 81,969 shares during the period. Vanguard Group Inc. grew its holdings in Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after purchasing an additional 186,165 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Intra-Cellular Therapies by 5.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 137,975 shares of the biopharmaceutical company’s stock valued at $2,243,000 after purchasing an additional 7,335 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Intra-Cellular Therapies by 59.9% during the first quarter. Goldman Sachs Group Inc. now owns 133,184 shares of the biopharmaceutical company’s stock valued at $2,164,000 after purchasing an additional 49,884 shares during the period. 59.55% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Alafi Capital Co Llc bought 258,065 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were bought at an average cost of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the transaction, the insider now owns 3,953,270 shares of the company’s stock, valued at $61,275,685. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 18,750 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $15.75, for a total value of $295,312.50. Following the completion of the sale, the chief executive officer now owns 1,107,457 shares in the company, valued at $17,442,447.75. The disclosure for this sale can be found here. 21.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/wells-fargo-company-mn-sells-55319-shares-of-intra-cellular-therapies-inc-itci.html.

Several research firms have issued reports on ITCI. Piper Jaffray Companies set a $10.00 price target on Intra-Cellular Therapies and gave the company a “hold” rating in a report on Thursday, August 10th. SunTrust Banks, Inc. raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, November 8th. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, August 9th. BidaskClub lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $25.00.

Intra-Cellular Therapies Inc. (ITCI) opened at $14.54 on Wednesday. Intra-Cellular Therapies Inc. has a 52-week low of $7.85 and a 52-week high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. During the same period in the previous year, the business earned ($0.70) earnings per share. The business’s revenue was up 675.0% on a year-over-year basis. analysts forecast that Intra-Cellular Therapies Inc. will post -2.16 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply